Immunotherapy-Chemo cocktail shows promise in tough breast cancer
NCT ID NCT03213041
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase II trial tested whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy carboplatin could help people with HER2-negative metastatic breast cancer that has spread. The 12 participants had cancer cells in their blood and had already tried other treatments. The goal was to see if the combo could slow cancer growth or improve survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab (Keytruda) combined with carboplatin chemotherapy
- What this could lead to
- If successful, this combination could offer a new treatment option for people with HER2-negative metastatic breast cancer that has not responded to prior therapies.
- What could go wrong
- This is a very small, early-phase trial with only 12 participants and no placebo group. The results may not apply to all patients, and the combination may cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESTROGEN RECEPTOR NEGATIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Digital therapy aims to tame the fear that haunts cancer survivors
- Can a vaccine train the immune system to hunt down hidden breast cancer cells?
- Gene test could guide breast cancer treatment to boost survival
- Genetic roadmaps for advanced cancer: study tests whether expert navigation boosts targeted therapy use
- Could a gentler chemo work for older breast cancer patients?